Personalis, Inc. (PSNL)

Market Cap	587.24M +108.5%
Revenue (ttm)	69.65M -17.7%
Net Income	-81.27M
EPS	-0.91
Shares Out	104.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,575,424
Open	5.99
Previous Close	5.90
Day's Range	5.59 - 6.10
52-Week Range	3.84 - 11.50
Beta	1.97
Analysts	Strong Buy
Price Target	12.20 (+117.47%)
Earnings Date	May 7, 2026

About PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 260
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL
• Website: https://www.personalis.com

Financial Performance

In 2025, Personalis's revenue was $69.65 million, a decrease of -17.69% compared to the previous year's $84.61 million. Losses were -$81.27 million, -0.02% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price target is $12.2, which is an increase of 117.47% from the latest price.

Price Target

$12.2

(117.47% upside)

Analyst Consensus: Strong Buy